More great news for Clinuvel, and yes why indeed not price sensitive? A quick search below comes up with 4 concrete examples of Orphan Drug Designation being granted and EACH ONE IS MARKET SENSITIVE as marked by the ASX. I could go on because there are plenty more but why the inconsistency. So what does Orphan Drug status do, it usually means tax credits for trials, a market exclusive period and less or no fees throughout the drug approval process.
Mesoblast MSB 15/02/24, Neuren NEU 3/9/21, Noxopharm NOX 4/10/23, Argenica AGN 15/11/23 All market sensitive but not CUV 29/4/24?
In my opinion this is very likely to be added as a label extension for the already approved and safe drug. Clinuvel did mention payors will reimburse for this terrible disease and the following statements in todays release are quite positive:
"The Committee for Orphan Medicinal Products (COMP) recognised the chronically severe nature of skin
symptoms in VP, the high unmet need, lack of alternative therapies, and afamelanotide’s potential as a VP
treatment.
The EMA considered clinical evidence from the CUV040 study – an open-label six-month study of six adult VP
patients – to be a sufficient proof-of-concept to enable a positive opinion on the ODD application for
SCENESSE®. The Agency reviewed the study endpoints and results on disease severity, ability to expose to
light, and quality of life as a potential clinical benefit for VP patients."
All IMO DYOR
- Forums
- ASX - By Stock
- Ann: SCENESSE European Orphan Drug Designation for VP
More great news for Clinuvel, and yes why indeed not price...
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.94 |
Change
-0.010(0.07%) |
Mkt cap ! $748.6M |
Open | High | Low | Value | Volume |
$14.91 | $15.00 | $14.71 | $242.0K | 16.21K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 1028 | $14.95 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.99 | 121 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1051 | 14.950 |
3 | 152 | 14.940 |
4 | 171 | 14.930 |
2 | 148 | 14.920 |
3 | 250 | 14.910 |
Price($) | Vol. | No. |
---|---|---|
14.990 | 121 | 6 |
15.000 | 2125 | 5 |
15.010 | 148 | 2 |
15.020 | 1475 | 3 |
15.030 | 147 | 2 |
Last trade - 10.29am 01/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online